Intra-Cellular Therapies, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule drugs for neuropsychiatric and neurological disorders. The company applies insights into intracellular signaling within the central nervous system to design compounds with differentiated receptor and pathway profiles.
Its lead product, lumateperone (CAPLYTA), is approved in the United States for the treatment of schizophrenia and for depressive episodes associated with bipolar I or II disorder in adults. The pipeline includes additional CNS candidates, including selective phosphodiesterase type 1 (PDE1) inhibitors and other next‑generation agents aimed at mood, psychotic, and neurodegenerative conditions. Intra-Cellular Therapies is headquartered in New York and is listed on Nasdaq under the ticker ITCI.